Progression from MCI to AD: predictive value of CSF Aß42 is modified by APOE genotype.
Neurobiol Aging
; 32(8): 1372-8, 2011 Aug.
Article
em En
| MEDLINE
| ID: mdl-19748159
ABSTRACT
OBJECTIVE:
To study CSF biomarkers amyloid-beta 1-42 (Aß42) and total tau (tau) in relation to APOE genotype in their ability to predict progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD).METHODS:
In 100 MCI patients CSF Aß42, tau and APOE genotype were determined. At follow-up of 18 (13-24) months 58 patients remained non-progressive and 42 progressed to AD.RESULTS:
Cox proportional hazards models showed an interaction between Aß42 and APOE genotype (p<0.05). Stratification for APOE revealed HR (95% CI) for abnormal Aß42 of 8.2 (2.1-31.9) for ε4 non-carriers, 3.9 (0.8-18.5) for heterozygotes and 0.3 (0.0-1.7) for homozygotes. Inversely, stratification for Aß42 revealed that in patients with normal levels of Aß42, ε4 homozygotes had a strongly increased risk of progression to AD with HR (95% CI) 20.8 (2.4-182.8). Tau and APOE independently predicted progression to AD.CONCLUSIONS:
Aß42 was a stronger predictor of progression to AD in APOE ε4 non-carriers than in carriers. Furthermore, the risk of progression for ε4 homozygotes was very high, also in patients with normal levels of Aß42.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Peptídeos beta-Amiloides
/
Apolipoproteína E4
/
Doença de Alzheimer
/
Disfunção Cognitiva
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article